| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.3K | 1.9% |
| Total Income | 2.3K | 1.9% |
| Expenditure | 1.5K | 6.7% |
| PBT | 758.00 | 6.4% |
| Net Profit | 601.00 | 4.8% |
| OPM | — | |
| NPM | 26.57% | 1.85pp |
| EPS | 1.42 | 0.7% |
Zoetis Announces Q1 2026 Results: Revenue $2.3 Billion, Up 3%
07 May 2026 · 7 May, 4:41 pm
Summary
Zoetis Inc. reported a revenue of $2.3 billion for Q1 2026, a 3% increase compared to Q1 2025. Net income was $601 million, or $1.42 per diluted share, showing flat performance but a 6% increase in diluted share. Adjusted net income reached $646 million, or $1.53 per diluted share, up by 2% and 9%, respectively. The company has revised its full-year 2026 revenue guidance to $9.680 - $9.960 billion and adjusted net income growth to 2% to 6%.
Key Highlights
- 1
Zoetis reported revenue of $2.3 billion for the first quarter of 2026, representing a 3% increase compared to the first quarter of 2025.
- 2
Net income for the first quarter of 2026 was $601 million, or $1.42 per diluted share, reflecting flat performance and growth of 6%, respectively, on a reported basis.
- 3
Adjusted net income for the first quarter of 2026 was $646 million, or $1.53 per diluted share, an increase of 2% and 9%, respectively, on a reported basis.
- 4
The company revised its full-year 2026 revenue guidance to $9.680 - $9.960 billion, with organic operational revenue growth of 2% to 5%.
- 5
Full year 2026 guidance for organic operational growth in adjusted net income is revised to 2% to 6%.
- 6
Guidance for diluted EPS on an adjusted basis is revised to $6.85 to $7.00.
- 7
Revenue in the International segment increased by 17% on a reported basis and 10% on an organic operational basis compared with the first quarter of 2025, reaching $1.1 billion.
Management Comments
Kristin Peck
“The first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products, where Zoetis leads. At the same time, competition intensified across key pet care categories, including dermatology and parasiticides. We are taking decisive action to sharpen commercial execution, unlock revenue and continue to drive disciplined cost management. The breadth of our portfolio remains a strength, reflected in the performance of International, livestock, and diagnostics in the quarter. With a robust pipeline of more than 12 potential blockbusters, a proven science-to-scale model that has consistently enabled us to compete and win, and a resilient, diversified business supported by strong industry fundamentals, we are well positioned to deliver our next wave of innovation and remain confident in our ability to deliver sustained value for shareholders."
Informational and educational content only. Not investment advice.